Journals / Kocaeli Tıp Dergisi / 2020 / Cilt: 9 - Sayı: 1

The Association Between Vascular Endothelial Growth Factor (VEGF) Levels And Prognosis In Patients Chronic Lymphocytic Leukemia

Kronik Lenfositik Lösemi Tanılı Hastalarda Vasküler Endotel Büyüme Faktör (VEGF) Düzeylerinin Prognozla İlişkisi

Pages
1–9
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

For this reason andbecause the simplicity of analyzing with ELISA, it can be auseful clinical parameter, after its importance have beenshown in larger and multi-variate studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: The Rai and Binet staging systems areused as a standard method to evaluate the prognosis of chroniclympocytic leukemia (CLL).
📊
Key Findings & Data:It issuggested that serum VEGF levels in CLL may be an importantparameter in determining the progression of the disease.METHODS: We detected the serum levels of VEGF in 46 CLLpatients and 20 healthy controls with the use of ELİSA method.RESULTS: The CLL patients group had higher median serumlevels of VEGF compared to the control group (267 pg / mL,43,8 pg/mL, p: 267 pg/ml) were associated with ashorter time of disease progression in Binet A and B CLLpatients (p: 0,004).
💡
Conclusion & Impact:For this reason andbecause the simplicity of analyzing with ELISA, it can be auseful clinical parameter, after its importance have beenshown in larger and multi-variate studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: The Rai and Binet staging systems areused as a standard method to evaluate the prognosis of chroniclympocytic leukemia (CLL). However, CLL is a heterogeneousdisease in terms of clinical features and prognosis. The Raiand Binet staging systems; may not reflect the differentbiological properties of CLL cells affecting survival outcomesand response to treatment. Because of this, new prognosticparameters has become important in the recent years. It issuggested that serum VEGF levels in CLL may be an importantparameter in determining the progression of the disease.METHODS: We detected the serum levels of VEGF in 46 CLLpatients and 20 healthy controls with the use of ELİSA method.RESULTS: The CLL patients group had higher median serumlevels of VEGF compared to the control group (267 pg / mL,43,8 pg/mL, p: 267 pg/ml) were associated with ashorter time of disease progression in Binet A and B CLLpatients (p: 0,004). We also found that high serum VEGFlevels showed a significant correlation with OS (p: 0,019).DISCUSSION and CONCLUSION: As a result, we found thatthe serum levels of VEGF in the CLL patients are higher thanthe control group and it can be a parameter associated withthe disease progression and survival. For this reason andbecause the simplicity of analyzing with ELISA, it can be auseful clinical parameter, after its importance have beenshown in larger and multi-variate studies.

Özet

GİRİŞ ve AMAÇ: Rai ve Binet evreleme sistemleri, kronik lenfositik lösemi (KLL)'nin prognozunu değerlendirmek için standart bir yöntem olarak kullanılırlar. Bununla birlikte, KLL klinik özellikler ve prognoz açısından heterojen bir hastalıktır. Rai ve Binet evreleme sistemleri; sağkalım sonuçlarını ve tedaviye cevabı etkileyen KLL hücrelerinin farklı biyolojik özelliklerini yansıtmayabilir. Bu nedenle, son yıllarda yeni prognostik parametreler önemli hale gelmiştir. KLL'deki serum VEGF düzeylerinin, hastalığın ilerlemesini belirlemede önemli bir parametre olabileceği önerilmektedir. YÖNTEM ve GEREÇLER: 46 KLL hastasında ve 20 sağlıklı kontrolde; serum VEGF düzeylerini ELISA yöntemi ile tespit ettik. BULGULAR: KLL hasta grubunda; sağlıklı kontrol grubuna göre daha yüksek ortalama serum VEGF düzeyleri saptandı (sırasıyla; 267 pg / mL, 43,8 pg/mL, p: 267 pg / ml), Binet A ve B KLL hastalarında daha kısa hastalık progresyonu süresi ile ilişkiliydi (p: 0,004). Ayrıca yüksek serum VEGF düzeylerinin OS ile anlamlı korelasyon gösterdiğini saptadık (p: 0,019). TARTIŞMA ve SONUÇ: Sonuç olarak, KLL hastalarındaki serum VEGF düzeylerinin kontrol grubundan daha yüksek olduğunu ve hastalığın ilerlemesi ve sağkalımı ile ilişkili bir parametre olabileceğini bulduk. Bu nedenle; ELISA ile serum VEGF kolay tespit edilmesi, daha büyük ve çok değişkenli çalışmalarda önemi gösterildikten sonra, yararlı bir klinik parametre olabilir.

🔖

Cite This Article

DEMİRSOY, E. T., AR, M. C. (2022). The Association Between Vascular Endothelial Growth Factor (VEGF) Levels And Prognosis In Patients Chronic Lymphocytic Leukemia. Kocaeli Tıp Dergisi, Cilt: 9 - Sayı: 1, 1–9. https://ajindex.com/articles/574747

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Cheson B, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87(12): 4990-4997
  2. Rozman C, Montserrat E. Current concepts: chronic lymphocytic leukemia. N Engl J Med. 1995; 333(16): 1052-1057
  3. Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia Hematology Am Soc Hematol Educ Program. 2015;2015:368-77
  4. Rai Kr, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46(2): 219-234
  5. Binet J, Augier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48(1): 198-206
  6. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R,et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338(21): 1506-1514
  7. Schweighofer CD, Cymbalista F, Muller C, Busch R, Porcher R,Langerbeins P et al. Early versus deferredtreatment with combined fludarabine, cyclophosphamide and rituximab(FCR) improves event-free survival in patients with high-risk Binet A chronic lymphocytic leukemia—first results of a randomized German-French cooperative phase III trial. Blood. 2013;122(21)
  8. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biology insights into clinical practice for patients with CLL. Blood. 2004; 103(4): 1202-1210
  9. Amaya-Chanaga CI, Rassenti LZ. Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. Best Pract Res Clin Haematol. 2016;29(1):79-89. 25. 10.Montillo M, Hamblin T, Hallek M,, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005; 90(3): 391-399
  10. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010(1):481-488. 26. 12.Shanafelt TD, KayNE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2):174-85
  11. Aguirre Palma LM, Gehrke I, Kreuzer KA. Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where